Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer

Stock Information for Sutro Biopharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Sutro Biopharma Inc.

Sutro Biopharma Announces Initiation of REFR?ME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer
Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFR?ME-O1 Trial
Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
Sutro Biopharma to Participate in Upcoming Investor Conferences
Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolR?-targeting ADC

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.